Adaptimmune Therapeutics Receives 'Moderate Buy' Consensus from Analysts

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has recently been given a consensus rating of "Moderate Buy" by five brokerages currently analyzing the stock, according to reports from Marketbeat.com. Among these analysts, one has recommended holding the stock, while four have given it a buy recommendation.

The average target price over the next twelve months set by these brokerages is $2.18, which paints a positive outlook for the company's stock.

Several analysts have recently shared their views on Adaptimmune's stock. Mizuho lowered its price target from $3.00 to $1.50 while maintaining an "outperform" rating. Additionally, StockNews.com began coverage of the stock on Friday, labeling it with a "buy" rating. Meanwhile, Wells Fargo reduced its price target from $2.00 to $1.50, giving the company an "equal weight" rating.

Lastly, Scotiabank adjusted their target price for Adaptimmune from $3.15 down to $1.40, also setting a "sector outperform" rating for the stock.

Adaptimmune Therapeutics' Stock Performance

On Friday, Adaptimmune's shares rose by 3.9%, trading at $0.29 with a volume of 4,999,050 shares exchanged, a significant increase compared to its average trading volume of 1,407,286. Currently, the company boasts a market capitalization of $74.41 million. Its price-to-earnings ratio stands at -1.32, and the beta value is 2.52. Adaptimmune's financial ratios show a quick ratio of 3.82 and a current ratio of 3.85, with a debt-to-equity ratio of 0.62. Over the past year, the stock has hit a low of $0.26 and a high of $1.65, with a 50-day moving average of $0.55 and a 200-day moving average of $0.71.

Institutional Investor Activity

In recent times, some institutional investors have made adjustments to their holdings in Adaptimmune Therapeutics. For instance, Invesco Ltd. increased its stake by 82.0%, now owning 63,335 shares valued at $34,000 after acquiring an additional 28,526 shares. Similarly, Two Sigma Advisers LP reported a hefty 492.0% increase in holdings, resulting in ownership of 70,735 shares worth $38,000 after purchasing an extra 58,787 shares.

Other institutional movements include Two Sigma Investments LP, which raised its position by 33.5% to own 76,347 shares valued at $41,000. Virtu Financial LLC also expanded its holdings by 21.5%, now owning 122,696 shares worth $66,000 after purchasing another 21,688 shares. As of now, approximately 31.37% of Adaptimmune's stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused primarily on developing innovative cell therapies for cancer patients in the U.S. and the U.K. The company's notable projects include the SPEARHEAD-1 trial, currently in phase II with ADP-A2M4 targeting synovial sarcoma, and the SURPASS-3 trial, also in phase II, focusing on ADP-A2M4CD8 for patients with platinum-resistant ovarian cancer. Furthermore, Adaptimmune is conducting phase I clinical trials in patients with head and neck and urothelial cancers.

Adaptimmune, Stock, Analysts